Elevate Skin Safety Standards with Zurko's Regularly-scheduled HRIPT Studies

Prior to launching any new product on the market, it’s important to evaluate its safety, especially for those products that will come into direct contact with the skin. The Human Repeat Insult Patch Test (HRIPT or RIPT test) is considered the gold standard for in vivo safety assessment, ensuring that tested products do not cause skin irritation or induce skin sensitivity. Additionally, conducting an HRIPT study enables you to evaluate the potential allergenicity of your product and is a crucial safety study to support the hypoallergenic claim.


For those in the cosmetics or personal care product industry, conducting safety evaluations through clinical testing, such as HRIPT, becomes an essential aspect of both product development and regulatory compliance.


At Zurko Research, our commitment to our clients and their consumers is steadfast. Through a wide range of safety clinical studies, including HRIPT, we strive to identify any potential irritation or sensitization issues, thus minimizing the risk of adverse reactions for consumers and ensuring the success of our clients.

"Gold standard for in vivo safety assessment"

Zurko Research HRIPT/RIPT capabilities

At Zurko Research our commitment to excellence is reflected in the meticulous approach we take in Human Repeat Insult Patch Test (HRIPT) studies. Our testing process consists of three different phases, ensuring a comprehensive evaluation of products that come into direct contact with the skin.


  • Three-phase application: Our HRIPT studies adhere to a standardized and meticulously structured three-phase application process, encompassing Induction, Rest, and Challenge phases. This rigorous methodology ensures the reliability and comprehensiveness of our results, aligning with established market practices. This approach is substantiated by research, including contributions from Marzulli F. and Maibach.


  • Increased testing frequency: Starting in 2024, we are enhancing our service by providing a minimum of 10 annual panels dedicated to HRIPT studies. This increased frequency offers greater flexibility in scheduling and meets the varied requirements of our clients. We always publish our annual calendar ahead of the year to come to  facilitating efficient planning and coordination.


  • Exclusive panels: tailoring our services to your requirements, we provide the option of exclusive HRIPT panels. This ensures a personalized focus on your products, maximizing the effectiveness of the study.


  • Panel size options: you may choose between panels of 50 or 100 subjects, allowing you to tailor the study to your specific needs. Furthermore, we can guarantee 100% of sensitive skin subjects in a 50-person to help you support the suitable for sensitive skin claim.


  • Expert dermatologist: every HRIPT study conducted at Zurko Research is supervised by our on-site dermatologist who also signs-off the study  report.

"10 HRIPT/RIPT panels from 2024 onwards"

Product claims supported by HRIPT studies

  • Dermatologist tested

  • Clinically tested
  • Non-irritating
  • Suitable for sensitive skin – if tested on subjects with sensitive skin
  • Hypoallergenic – a claim that should also be reviewed along with the formula and its ingredients

"On-site dermatologist"

Products that can be subjected to HRIPT/RIPT

  • Skin care products, including creams, lotions, serums
  • Makeup products
  • Personal care products, such as shampoos and body washes (diluted)
  • Therapeutic products
  • Soaps
  • Specialty ingredients (in a carrier base)